Glen Eagle Advisors, LLC
- SEC CIK
- 0002029317
- Latest filing
- Aug 14, 2026
DFTX holding history
Definium Therapeutics, Inc. in every 13F filed by Glen Eagle Advisors, LLC, including the quarters it was sold out or no filing was made. Changes compare share counts with the previous calendar quarter.
DFTX overviewAll 13F holders of DFTXFull Q2 2026 holdings
- Shares (Q1 2025)
- 0
- Sold out in Q1 2025
- Value
- $0
- % of portfolio
- 0.0%
- Quarters held
- 13
- Since Q2 2021
| Quarter | Shares | Value | % of portfolio | Share change | Action | All holders |
|---|---|---|---|---|---|---|
| Q1 2025 | 0 | $0 | 0.0% | −6−100.0% | Sold out | Holders |
| Q4 2024 | 6 | $42 | <0.1% | 00.0% | Unchanged | Holders |
| Q3 2024 | 6 | $34 | <0.1% | 00.0% | Unchanged | Holders |
| Q2 2024 | 6 | $43 | <0.1% | 00.0% | Unchanged | Holders |
| Q1 2024 | 6 | $56 | <0.1% | 00.0% | Unchanged | Holders |
| Q4 2023 | 6 | $22 | <0.1% | 00.0% | Unchanged | Holders |
| Q3 2023 | 6 | $19 | <0.1% | −24−80.0% | Reduced | Holders |
| Q2 2023 | 30 | $108 | <0.1% | 00.0% | Unchanged | Holders |
| Q1 2023 | 30 | $95 | <0.1% | 00.0% | Unchanged | Holders |
| Q4 2022 | 30 | $66 | <0.1% | −22−42.3% | Reduced | Holders |
| Q3 2022 | 52 | $182 | <0.1% | −1−1.6% | ReducedConverted for a 1-for-15 split | Holders |
| Q2 2022 | 793 | $508 | <0.1% | +360+83.1% | Added | Holders |
| Q1 2022 | 433 | $481 | <0.1% | +433 | New | Holders |
| Q3 2021 | 0 | $0 | 0.0% | −433−100.0% | Sold out | Holders |
| Q2 2021 | 433 | $1.51K | <0.1% | +433 | New | Holders |